Blueprint Medicines Corp (BPMC) Insider Trading
- $348,278.00
- $177,560,027.15
- March 24, 2025
- Jeffrey W Albers
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Nov. 15, 2017 | Director | 5,000 | $63.38 | Sell | $316,900.00 | |
| Nov. 6, 2017 | Insider | 5,000 | $70.40 | Sell | $352,000.00 | |
| Nov. 6, 2017 | CEO | 30,000 | $70.31 | Sell | $2,109,300.00 | |
| Oct. 5, 2017 | Insider | 5,449 | $66.44 | Sell | $362,031.56 | |
| Sept. 18, 2017 | Director | 2,500 | $60.00 | Sell | $150,000.00 | |
| Sept. 18, 2017 | Insider | 6,356 | $60.03 | Sell | $381,550.68 | |
| Aug. 9, 2017 | Insider | 5,000 | $48.60 | Sell | $243,000.00 | |
| Aug. 8, 2017 | CEO | 30,000 | $49.62 | Sell | $1,488,600.00 | |
| Aug. 7, 2017 | CEO | 20,000 | $49.08 | Sell | $981,600.00 | |
| July 5, 2017 | Director | 7,500 | $55.06 | Sell | $412,950.00 | |
| July 5, 2017 | Insider | 7,265 | $54.66 | Sell | $397,104.90 | |
| June 28, 2017 | Director | 32,500 | $50.28 | Sell | $1,634,100.00 | |
| June 28, 2017 | Insider | 6,357 | $50.00 | Sell | $317,850.00 | |
| June 28, 2017 | CEO | 20,000 | $50.47 | Sell | $1,009,400.00 | |
| March 16, 2017 | Major Shareholder | 30,000 | $40.88 | Sell | $1,226,400.00 | |
| Feb. 7, 2017 | Major Shareholder | 1,000,000 | $35.28 | Sell | $35,280,000.00 | |
| Dec. 19, 2016 | Major Shareholder | 106,489 | $28.19 | Sell | $3,001,924.91 | |
| Dec. 1, 2016 | Director | 200 | $30.02 | Sell | $6,004.00 | |
| Oct. 13, 2016 | Director | 21,800 | $30.02 | Sell | $654,436.00 | |
| Aug. 8, 2016 | CEO | 17,000 | $22.86 | Sell | $388,620.00 | |
| June 3, 2016 | CEO | 17,000 | $20.03 | Sell | $340,510.00 | |
| April 13, 2016 | Insider | 15,872 | $20.01 | Sell | $317,598.72 | |
| April 12, 2016 | Insider | 18,853 | $20.14 | Sell | $379,699.42 | |
| April 6, 2016 | CEO | 17,000 | $20.42 | Sell | $347,140.00 | |
| Dec. 17, 2015 | insider | 31,119 | $25.05 | Sell | $779,530.95 | |
| Nov. 27, 2015 | Insider | 287,415 | $21.48 | Sell | $6,173,674.20 | |
| Nov. 24, 2015 | Insider | 161,271 | $20.14 | Sell | $3,247,997.94 | |
| Nov. 23, 2015 | Insider | 189,572 | $20.15 | Sell | $3,819,875.80 | |
| Nov. 19, 2015 | Insider | 237,218 | $19.76 | Sell | $4,687,427.68 | |
| Nov. 17, 2015 | Insider | 27,490 | $20.60 | Sell | $566,294.00 | |
| Nov. 3, 2015 | insider | 84,998 | $21.05 | Sell | $1,789,207.90 |
Insiders are both buying and selling Blueprint Medicines Corp stock.
The insider traders at Blueprint Medicines Corp are: Jeffrey W Albers, Ariel Hurley, Kate Haviland, Christina Rossi, Daniel Lynch, L. Becker Hewes, Christopher K Murray, George Demetri, Nicholas Lydon, Marion Dorsch, Debra Durso-Bumpus, Anthony L Boral, Tracey L Mccain, Fmr Llc, Michael Landsittel, Christoph Lengauer, Mark Alan Goldberg, Fouad Namouni, Percy H Carter, Charles A Rowland Jr, Rock Ventures Ii L.P. Third, Kevin P. Starr, Lonnel Coats, Mark J Levin, Alexis Borisy, and Philina Lee
The most active insider trader at Blueprint Medicines Corp is Jeffrey W Albers with 41 trades.
Rock Ventures Ii L.P. Third has sold the most Blueprint Medicines Corp stock with a total value of $70,560,000.00.
Mark Alan Goldberg has bought the most Blueprint Medicines Corp stock with a total value of $599,800.00.
The most recent insider trade for Blueprint Medicines Corp was on March 24, 2025.
The single biggest insider buy for Blueprint Medicines Corp was from Mark Alan Goldberg with a total value of $299,900.00 on March 3, 2022.
The single biggest insider sell for Blueprint Medicines Corp was from Rock Ventures Ii L.P. Third with a total value of $35,280,000.00 on Feb. 7, 2017.